Belatacept for the prevention of organ rejection in kidney transplantation
For information belatacept was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 87
- Referral date:
- 01 July 2009
- Topic area
- Urogenital
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Project Team
- Communications manager:
- Paul Cooney
- Executive Lead:
- Peter Littlejohns
- Project manager:
- Kate Moore
- Technical Lead:
- Joao Vieira
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Note added to the project documents |
| 26 February 2016 | Discontinued. For information belatacept was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481 |
For further information on our processes and methods, please see our CHTE processes and methods manual